Conducting clinical trials during the COVID-19 pandemic

被引：13

作者：

Collier, Erin K. ^{[1
]}

Hsiao, Jennifer L. ^{[2
]}

Shi, Vivian Y. ^{[3
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA

[3] Univ Arizona, Dept Med, Div Dermatol, Tucson, AZ USA

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2020年 / 31卷 / 04期

关键词：

Clinical trials; compliance; COVID-19; safety;

D O I：

10.1080/09546634.2020.1759770

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The COVID-19 pandemic has greatly impacted dermatology clinical trial operations due to mandated governmental and institutional shut-downs and newly implemented restrictions. During this unprecedented time, measures should be taken to maintain research conduct compliance while also ensuring the safety of trial staff and participants. Herein, we underscore the challenges facing dermatology trials during the COVID-19 pandemic, and offer strategies to maintain compliant and safe conduct.

引用

页码：330 / 332

页数：3

共 6 条

[1]

[Anonymous], CONSIDERATIONS RELAT

[2]

[Anonymous], 2020, FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards

[3]

[Anonymous], 2020, CTR DIS CONTROL PREV, V69, P1

[4]

[Anonymous], GUIDANCE MANAGEMENT

[5]

CRU, 2020, MICR INF PAP, P1

[6] COVID-19 and immunomodulator/immunosuppressant use in dermatology [J].

Price, Kyla N. ;

Frew, John W. ;

Hsiao, Jennifer L. ;

Shi, Vivian Y. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (05) :E173-E175

← 1 →